Molecular Signature for Lymphatic Invasion Associated with Survival of Epithelial Ovarian Cancer.
- Author:
E Sun PAIK
1
;
Hyun Jin CHOI
;
Tae Joong KIM
;
Jeong Won LEE
;
Byoung Gie KIM
;
Duk Soo BAE
;
Chel Hun CHOI
Author Information
- Publication Type:Original Article
- Keywords: Gene expression signature; Ovarian neoplasm; Human genome; Lymphatic metastasis
- MeSH: Disease-Free Survival; DNA; Forests; Gene Expression; Genome; Genome, Human; Humans; Logistic Models; Lymphatic Metastasis; Ovarian Neoplasms*; RNA, Messenger; ROC Curve; Support Vector Machine; Transcriptome
- From:Cancer Research and Treatment 2018;50(2):461-473
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: We aimed to develop molecular classifier that can predict lymphatic invasion and their clinical significance in epithelial ovarian cancer (EOC) patients. MATERIALS AND METHODS: We analyzed gene expression (mRNA, methylated DNA) in data from The Cancer Genome Atlas. To identify molecular signatures for lymphatic invasion, we found differentially expressed genes. The performance of classifier was validated by receiver operating characteristics analysis, logistic regression, linear discriminant analysis (LDA), and support vector machine (SVM). We assessed prognostic role of classifier using random survival forest (RSF) model and pathway deregulation score (PDS). For external validation, we analyzed microarray data from 26 EOC samples of Samsung Medical Center and curatedOvarianData database. RESULTS: We identified 21 mRNAs, and seven methylated DNAs from primary EOC tissues that predicted lymphatic invasion and created prognostic models. The classifier predicted lymphatic invasion well, which was validated by logistic regression, LDA, and SVM algorithm (C-index of 0.90, 0.71, and 0.74 for mRNA and C-index of 0.64, 0.68, and 0.69 for DNA methylation). Using RSF model, incorporating molecular data with clinical variables improved prediction of progression-free survival compared with using only clinical variables (p < 0.001 and p=0.008). Similarly, PDS enabled us to classify patients into high-risk and low-risk group, which resulted in survival difference in mRNA profiles (log-rank p-value=0.011). In external validation, gene signature was well correlated with prediction of lymphatic invasion and patients' survival. CONCLUSION: Molecular signature model predicting lymphatic invasion was well performed and also associated with survival of EOC patients.
